Trials in Chicago, Illinois
Here are the top 10 medical studies for prostate cancer in Chicago, Illinois
Popular Filters
Phase 3 Trials
AKT Inhibitor
Capivasertib + Abiraterone for Prostate Cancer
Recruiting1 awardPhase 3
Chicago, Illinois
This trial will compare the efficacy of capivasertib+abiraterone+androgen deprivation therapy to placebo+abiraterone+androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC) whose tumours are PTEN-deficient. The primary endpoint is radiographic progression-free survival.
PARP Inhibitor
Rucaparib + Enzalutamide for Prostate Cancer
Recruiting1 awardPhase 3
Chicago, Illinois
This trial is testing if a combination of two drugs, rucaparib and enzalutamide, is better than enzalutamide alone for treating men with prostate cancer that has spread and become resistant to testosterone-deprivation therapy.
Radioisotope Therapy
177Lu-PSMA-617 + Standard Therapy for Prostate Cancer
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial tests if adding a radioactive drug to standard hormone treatments can better treat men with advanced prostate cancer. The drug targets and kills cancer cells with radiation, while standard treatments block hormones that help cancer grow.
Radioisotope Therapy
177Lu-PSMA-617 vs. ARDT for Prostate Cancer
Recruiting2 awardsPhase 3
Milwaukee, Wisconsin
This trial is comparing two different treatments for men with metastatic castration resistant prostate cancer who have previously been treated with an alternate androgen receptor downregulation therapy. The study will compare how well each treatment improves the participant's rPFS (progression free survival) or death.
Trials With No Placebo
Virus Therapy
ST101 for Advanced Cancer
Recruiting1 awardPhase 1 & 2
Warrenville, Illinois
This trial tests a new drug, ST101, given to patients with advanced cancers who haven't responded to other treatments. The study aims to find the safest and most effective dose. It includes patients with specific types of breast cancer, melanoma, brain cancer, and prostate cancer.
BET Bromodomain Inhibitor
ZEN-3694 + Enzalutamide + Pembrolizumab for Prostate Cancer
Recruiting1 awardPhase 2
Evergreen Park, Illinois
This trial is testing a combination of drugs to treat patients with prostate cancer that has spread and is resistant to hormone therapy. The drugs work in different ways to attack the cancer cells.
Gene Expression Classifier
Genetic Testing for Prostate Cancer
Recruiting1 award6 criteria
Holland, Michigan
This trial studies how GEC testing can improve prostate cancer care by analyzing gene activity to better predict cancer aggressiveness. It targets prostate cancer patients to help make more informed treatment decisions.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.